Novartis India Faces ₹10.28 Crore Tax Demand; Company Appeals Order

Novartis India Limited has received a demand notice and order from the Income Tax Department for Assessment Year 2020-21, totaling ₹10,28,40,780. This demand comprises ₹5,75,85,157 in principal and ₹4,52,55,623 in interest. The notice relates to alleged non-compliance with Tax Deducted at Source (TDS) provisions concerning stockist margins and payments to Micro, Small and Medium Enterprises (MSMEs).

The company intends to appeal the order with the appropriate tax authority and will seek a stay on the payment. Failure to contest or secure a stay could affect the company's financial results and liquidity, while the legal process adds to administrative costs.

Company Background

Novartis India Limited, established in 1947, is a significant company in India's pharmaceutical market, trading drugs and pharmaceuticals across areas such as cardiovascular, oncology, immunology, and neuroscience.

This tax issue is not the first for Novartis entities in India. A related entity, Novartis Healthcare Private Limited, also faced TDS issues for AY 2020-21 regarding stockist margins and MSME payments. Novartis India Limited has a history of tax disputes, involving appeals on penalties and tax treatment of income components from earlier years.

Recently, Novartis AG announced the sale of its stake in the listed Novartis India Limited to Chris Capital, as part of a strategy to focus on innovative medicines. The company has stated that India remains a strategic market, with operations continuing via its subsidiary, Novartis Healthcare Private Limited.

Next Steps and Risks

Novartis India will now file an appeal with the appropriate tax authority and seek a stay order to halt payment obligations until the appeal process concludes. The company's legal and finance teams will handle this process.

The main risk for Novartis India is that the appeal may fail, requiring full payment of the tax demand and interest. Non-compliance, if confirmed, could also lead to penalties under Section 271C of the Income Tax Act. The proceedings may extend, causing ongoing uncertainty and additional expenses.

Investors will monitor updates on the appeal and stay application, the timeline for the appellate proceedings, any new directives from the Income Tax Department, and company commentary on potential financial impacts.